ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
- Submitting institution
-
University of Newcastle upon Tyne
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 241736-177401-1266
- Type
- D - Journal article
- DOI
-
10.1016/j.jtho.2017.07.005
- Title of journal
- Journal of Thoracic Oncology
- Article number
- -
- First page
- 1357
- Volume
- 12
- Issue
- 9
- ISSN
- 1556-0864
- Open access status
- Deposit exception
- Month of publication
- July
- Year of publication
- 2017
- URL
-
https://doi.org/10.1016/j.jtho.2017.07.005
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
18
- Research group(s)
-
C - Cancer
- Citation count
- 80
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- a. The author made a substantial contribution either to the conception or design of the study a. The author made a substantial contribution to the organisation of the conduct of the study b. The author helped draft the output
- Non-English
- No
- English abstract
- -
